From: Evaluation of hypoglycemic and anti-hyperglycemic potential of Tridax procumbens (Linn.)
Group (n = 6) | Dose (mg/kg) | Alloxaα) dosing | Days after dosing | ||||
---|---|---|---|---|---|---|---|
 |  |  | 0 dβ) | 7 d | 15 d | 21 d | 30 dγ) |
Normal Control | - | 81.21 ± 2.1a | 79.00 ± 1.8a | 86.12 ± 2.0a | 77.45 ± 2.6a | 83.20 ± 3.1a | 80.16 ± 3.6a |
Normal+ Extract | 250 | 78.54 ± 2.4a | 77.20 ± 2.6a | 79.20 ± 3.5a | 76.56 ± 4.8a | 75.00 ± 3.5a | 76.60 ± 3.0a |
Normal+ Extract | 500 | 83.20 ± 1.8a | 80.63 ± 3.0a | 84.25 ± 2.9a | 79.36 ± 6.2a | 74.25 ± 5.2a | 73.60 ± 5.8b |
Diabetic Control | - | 80.16 ± 1.6a | 452.35 ± 4.6b | 470.20 ± 6.2b | 459.48 ± 11.2b | 495.00 ± 9.2c | 512.40 ± 9.6c |
Diabetic+ Extract | 250 | 82.00 ± 2.8a | 454.16 ± 5.4b | 299.30 ± 10.2c (34.09) | 215.00 ± 9.6d (28.16) | 186.82 ± 14.7e (13.10) | 171.24 ± 12.5f (8.33) |
Diabetic+ Extract | 500 | 84.40 ± 2.4a | 468.20 ± 4.6b | 289.50 ± 8.6c (38.16) | 204.20 ± 12.3d (29.46) | 179.42 ± 11.6e (12.13) | 166.00 ± 10.2f (7.47) |
Diabetic+ Glibenc-lamide | 10 | 79.78 ± 2.1a | 483.83 ± 6.8b | 394.14 ± 9.2c (18.53) | 293.20 ± 14.3d (25.61) | 258.40 ± 12.9e (11.86) | 242.00 ± 11.4e (6.34) |